Abstract
Identification of Potential Prognostic

Introduction
Liver cancer is prevalent in China and has become the fourth leading cause of male cancerrelated death [1] . The global cancer statistics demonstrate that the number of new cases and deaths from liver cancer in China account for more than half the worldwide total [2] . Most liver cancers are diagnosed as hepatocellular carcinoma (HCC) [3] . Hepatocarcinogenesis is driven by the interaction of genetic and environmental factors [4, 5] . The main environmental factors associated with HCC are hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection and alcohol abuse [4] . Well-known genetic factors include the TP53 mutation, CTNNB1 mutation, methylation and dysregulation of cancer-relevant genes [4, 5] . The development of high-throughput technologies enabled researchers to investigate a variety of approaches for identifying the genetic factors associated with HCC through genome-wide screening, such as genome-wide association studies [6] , genome-wide expression profiles [7] and comprehensive analysis of multiple genome-wide approaches [8] .
Recent research advances support that the proportion of the genome termed noncoding RNAs (ncRNAs) reflects the complexity of the genome in higher eukaryotes [9, 10] . Among ncRNAs, long non-coding RNA (lncRNA), have been studied extensively and shown to play indispensable roles in many biological processes, and increasing evidence suggests that dysregulated lncRNAs are associated with HCC tumorigenesis, metastasis, and prognosis [11] [12] [13] .
A growing number of studies demonstrate that aberrantly expressed lncRNAs serve as potential biomarkers for predicting HCC prognosis [14, 15] . Therefore, systematic efforts to investigate an expression-based lncRNA signature for prognosis prediction in patients with HCC are necessary. Genome-wide screening analysis is an effective method for the identification of the potential biomarkers for HCC diagnosis and prognosis prediction. The Cancer Genome Atlas (TCGA) is a project aimed at generating multi-dimensional maps of the key genomic changes in 33 types of cancer to discover potential genetic biomarkers for cancer prevention, diagnosis, and therapy based on comprehensive genomic data analysis [16] . The aim of the present study was to identify potential prognostic lncRNA biomarkers for predicting survival in patients with HCC using TCGA datasets and bioinformatics analysis.
Materials and Methods
Data source
An RNA sequencing (RNA-Seq) dataset of 371 HCC patients was obtained from TCGA data portal (https://portal.gdc.cancer.gov/, accessed November 5, 2017), including 374 HCC tumor tissues and 50 adjacent normal liver tissues [8] . The corresponding clinical information of TCGA HCC patients was download from the University of California Santa Cruz Xena browser (UCSC Xena: http://xena.ucsc.edu/, accessed November 5, 2017) . Because the data were downloaded from TCGA, study approval by an ethics committee was not necessary. Data acquisition and application complied with TCGA publication guidelines and data access policies.
Screening of differentially expressed lncRNAs
Genome-wide lncRNA expression profiles were obtained from the RNA-Seq dataset of TCGA, which consists of mRNA and lncRNA expression data. LncRNAs with mean values of >1 were included in the differentially expressed lncRNA (DEL) screening. The edgeR [17] and DESeq [18] packages of the R platform were used for DEL screening. A false discovery rate (FDR) < 0.05 and |log2 fold change (log2FC)| ≥ 1 were identified as DELs in the comparison of expression levels between HCC tumor and adjacent normal liver tissues. The overlapping DELs between edgeR and DESeq were used for further analysis.
Construction of the DEL expression-based prognostic signature
The survival information of one HCC patient from TCGA was unknown, therefore, 370 HCC patients were finally included in the survival analysis. A univariate Cox regression analysis was performed using the survival package to examine the association between the expression levels of DELs and the overall survival (OS) of patients with HCC. DELs with a P-value <0.001 were considered prognostic DELs with expression levels significantly associated with OS. Prognostic DELs with a P-value of <0.001 in the survival analysis were further assessed using the "step" function to select the optimal combination. The prognostic DELs selected by the "step" function were used for construction of the prognostic model. The relative contribution of these prognostic DELs in HCC survival prediction was evaluated by fitting them into a multivariate Cox regression analysis with OS as the dependent variable. A DEL expression-based prognostic risk score model was constructed using the linear combination of the expression levels of DELs with the multivariate Cox regression coefficient (β) as the weight. The risk score formula was as follows: risk score = expression of DEL 1 × β 1 DEL 1 + expression of DEL 2 × β 2 DEL 2 +…expression of DEL n × β n DEL n [19] [20] [21] . This DEL prognostic model was used to divide HCC patients into high-and low-risk groups using the median score of the DEL expression-based risk scores. A time-dependent receiver operating characteristic (ROC) curve was generated using the survivalROC package in the R platform to evaluate the accuracy of the DEL expressionbased prognostic signature for predicting OS in HCC [19] .
Comprehensive analysis of the DEL expression-based prognostic signature
The prognostic model was evaluated by performing a comprehensive analysis of the DEL expressionbased prognostic signature. The expression levels of the prognostic DELs were compared between the lowand high-risk groups. In addition, the predictive value of the risk score for clinical status was investigated. Stratified analysis and joint effect analysis were performed to investigate the association between the risk score and clinical status in HCC.
Functional assessment and bioinformatics analysis
Generally, lncRNAs do not encode proteins, and their function is associated with coexpressed proteincoding genes (PCGs) [22, 23] . The coexpression relationship between prognostic DELs and PCGs was evaluated using Pearson's correlation coefficient. Coexpressed PCGs were subjected to functional enrichment analysis to predict the biological function of the prognostic DELs using the Database for Annotation, Visualization, and Integrated Discovery version 6.7 (DAVID v6.7, https://david.ncifcrf.gov/, accessed November 5, 2017), which is a widely used bioinformatics resource [24] [25] [26] . GO terms and KEGG pathways with a P-value <0.05 and enrichment score >1.0 were considered as significantly enriched functional annotations.
The mRNA expression data of the PCGs were obtained from the same TCGA HCC patients and the same RNA-Seq dataset. Moreover, data processing of the PCG mRNA dataset was performed in the same manner as that of the lncRNA dataset, which was normalized by DESeq packages in the R platform. Prognostic DELs and PCGs with a Pearson correlation coefficient of > 0.4 were considered lncRNA-correlated PCGs, and used for coexpression network construction and prognostic DEL functional assessment. A coexpression network between prognostic DELs and the corresponding PCGs was constructed using Cytoscape software (version 3.4.0; http://www.cytoscape.org/, accessed November 5, 2017) [27] .
Gene set enrichment analysis (GSEA v.2-2.2.3: http://software.broadinstitute.org/gsea/index.jsp; accessed November 5, 2017) was performed to investigate the potential mechanisms underlying the effect of the risk score on HCC prognosis [28, 29] . The Molecular Signatures Database (MSigDB) of c2 (c2.cp.kegg. v6.1.symbols.gmt) and c5 (c5.all.v6.1.symbols.gmt) was used to assess the functional differences between the low-and high-risk groups [30] . The enrichment gene sets in the GSEA that reached a nominal P-value <0.05 and FDR <0.25 were considered significant.
Results
DEL screening
Comprehensive gene annotation was downloaded from the Ensembl Genomes (Homo_sapiens.GRCh38.90.gtf:
http:// www.ensembl.org/index.html, accessed November 5, 2017) [34, 35] . Of the 14, 447 lncRNAs obtained from the RNA-Seq dataset, 6, 938 lncRNAs met the criterion of a mean value >1 and were included in the DEL screening. In the present study, 2626 lncRNAs were identified as DELs using edgeR (Fig. 1A, Table S1 ), whereas, 842 lncRNAs were identified as DELs using DESeq (Fig. 1B, Table S2 ). For all supplemental material see www.karger. com/doi/10.1159/000492507. The 827 DELs that overlapped in the edgeR and DESeq screening were used for further analysis (Fig. 1C) . The heat map of the 827 DELs is shown in Fig. 2 .
Construction of the DEL-based prognostic signature
A univariate Cox regression analysis was performed to examine the association between DELs and the OS of patients with HCC. The results are shown in Table S3 . Fortyseven DELs with a P-value <0.001 were regarded as prognostic DELs and selected using the "step" function to screen for the Fig. 3N , respectively. The relative contribution of these prognostic DELs to survival prediction was determined using multivariate Cox regression analysis. The risk score formula was as follows: risk score = expression of AC015908. Table  2 . Tumor stage and radical resection that were significantly associated with HCC OS in the univariate analysis were included in the multivariate Cox proportional hazards regression model for adjustment. Survival analysis indicated that the 13-DEL prognostic signature could separate HCC patients into low-risk and high-risk groups, and HCC patients with high-risk scores had (Fig. 4C ), respectively. The expression level distribution of the 13 prognostic DELs in the low-and high-risk groups are presented in Fig. 4D . In addition, we investigated the relationship between the 13-DEL prognostic signature and various clinical features ( 
Stratified and joint effects analysis
To investigate the prognostic prediction value of the 13-DEL prognostic signature under different clinical conditions, stratified and joint effects analyses were performed after adjusting for tumor stage and radical resection. In the stratified analysis, high-risk scores predicted a significantly increased risk of death in patients with all favorable strata and all adverse strata except in patients without radical resection and serum AFP > 400 ng/ mL (Fig. 6A) , indicating that the risk score is independent from clinical information. To facilitate the use of the risk score, a survival nomogram was plotted (Fig. 6B) based on 155 patients with complete clinical information and considering the risk scores and the clinicopathological observations. Consistent with the survival analysis, the risk score contributed the greatest number of risk points (ranged 0-100), whereas the other clinical information had a considerably lower 
contribution.
Joint effects analysis of the 13-DEL prognostic signature and clinical features indicated that the prognostic signature performed well in clinical outcome prediction, and in combination with clinical features, it showed a strong interaction and better predictive value for HCC prognosis (Fig. 7A-G and Table 3 ).
Functional assessment and bioinformatics analysis
A total of 17, 682 PCGs were extracted from the TCGA HCC patients' dataset and used for coexpression network construction. The Pearson correlation coefficients of 686 Cellular Physiology and Biochemistry
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lncRNA-correlated PCGs with 738 edges greater than 0.4 were included in the coexpression network ( Fig. 8 and Table S4 ). To investigate the potential functional roles of these 13 prognostic lncRNAs in HCC, we performed functional enrichment analysis of lncRNA-correlated PCGs using DAVID v6.7. GO term enrichment analysis suggested that these lncRNA-correlated PCGs were significantly enriched in 273 GO terms (Table S5) , of which cell cycle-related biological processes were frequently enriched (Fig. 9A) . Consistent with the GO enrichment analysis, KEGG enrichment analysis confirmed that these lncRNA-correlated PCGs were significantly enriched in the cell cycle pathway. Additionally, the peroxisome proliferator-activated receptor (PPAR) signaling pathway and multiple metabolic pathways were also enriched, including glyoxylate and dicarboxylate metabolism, metabolism of xenobiotics by cytochrome P450, beta-alanine metabolism, and propanoate metabolism (Fig. 9B) .
GSEA analysis of the low-and high-risk groups supported the results of functional enrichment analysis for lncRNA-correlated PCGs. Cell cycle-related biological processes and pathways, and the PPAR signaling pathway were significantly enriched (Table S6 and S7; Fig.  10A-F) , indicating that the 13-DEL prognostic signature may have a marked influence on these biological processes and pathways in HCC.
Discussion
TCGA is a comprehensive expression database of multiple types of cancer. Several recent studies used the lncRNA dataset from TCGA to investigate the potential use of lncRNAs for cancer diagnosis and prognosis prediction. He et al., Tang et al. and Zang et al. used TCGA lncRNA dataset to identify a lncRNA expression-based prognostic signature for assessing the survival of patients with soft-tissue sarcoma, lung cancer, and colorectal adenocarcinoma [36] [37] [38] . TCGA lncRNA datasets of cutaneous melanoma [39] , bladder urothelial carcinoma [40] , breast cancer [41] , clear cell renal cell carcinoma [42] , gastric cancer [43, 44] , head and neck squamous cell carcinoma [45] , and HCC [46] have been used in lncRNA expressionbased prognostic signature investigations by other researchers. These studies used a genome-wide screening method to identify potential prognostic lncRNAs and calculated a risk score based on lncRNA expression. This is an effective method to screen for prognostic lncRNAs and investigate their optimal combination for prognosis prediction.
Numerous studies by multiple researchers, who systematically and comprehensively reviewed the existing literature on the role of lncRNAs in HCC indicate that lncRNAs can be dysregulated in HCC and play a critical role in hepatocarcinogenesis, metastasis, as therapeutic targets, and in prognosis or diagnosis [14, 47, 48] . Yang et al. identified numerous recurrently deregulated tumorigenesis-and metastasis-associated lncRNAs, and most of these were experimentally validated and mechanistically linked to cancer development and progression [49] . Yuan et al. reported that a lncRNA associated with microvascular invasion in HCC (lncRNA MVIH) was frequently overexpressed in HCC patients with microvascular invasion, and deregulation of lncRNA MVIH serves as a predictor for poor OS and recurrencefree survival after hepatectomy [12] . Because lncRNAs play important roles in HCC, it is necessary to identify potential lncRNA biomarkers in HCC, and the use of TCGA HCC lncRNA dataset is a reliable method.
In the present study, we identified 827 DELs via the edgeR and DESeq packages, and identified 13 DELs that were suitable for the construction of a prognostic signature through screening with the ''step'' function. The DEL-based prognostic signature performed well in HCC prognosis prediction, and the time-dependent ROC analysis showed that it performed well in 1-, 3-, and 5-year survival prediction. In addition, the DEL-based prognostic signature identified in the present study performed well compared with the previous prognostic signature reported by Wang et al., and the prediction accuracy was significantly improved (AUC in 5-year survival prediction: 0.79 vs. 0.701, respectively) [46] . Consistent with previous findings, AC093609.1 and AC124067.4 were also identified as HCC prognostic DELs in the present analysis [46] . In addition, AC124067.4, also known as RP11-150O12.3, was previously identified as a prognostic DEL in a TCGA lncRNA-based prognostic signature investigation in colorectal adenocarcinoma and gastric cancer [38, 44] . A previous study showed that the expression levels of TMCC1-AS1, which was included in the 13-DEL prognostic signature, are associated with OS in patients with HCC [50] . Yu et al. reported that another prognostic DEL, FOXD2-AS1, was significantly differentially expressed in association with the progression of gastric cancer, and high FOXD2-AS1 expression was associated with a significantly increased risk of death [51] . Similar results regarding FOXD2-AS1 were reported in non-small cell lung cancer. Rong et al. showed that high expression of FOXD2-AS1 promotes non-small cell lung cancer progression via Wnt/β-catenin signaling and is associated with poor OS [52] . A study in colorectal cancer (CRC) also suggested that FOXD2-AS1 was significantly upregulated in tumor tissues and acts as a tumor promoter in CRC, inducing CRC progression by regulating epithelial-mesenchymal transition and the Notch signaling pathway [53] . Transcriptional fingerprint analysis in pancreatic ductal adenocarcinoma (PDAC) demonstrated that F11-AS1 is downregulated in PDAC tumor tissues and cell lines. These results suggest that dysregulated lncRNAs play important roles in PDAC development and progression [54] . A literature review revealed that the remaining prognostic DELs identified in the present study were not reported previously, and their function in HCC and other cancers needs to be further investigated and verified. The present findings have limitations because they were obtained from a single cohort; therefore, external validation cohorts are necessary to confirm the present results.
Survival analysis of the DEL-based prognostic signature in the present study showed a significantly different clinical outcome after stratification by risk score. Stratification according to risk score and clinical features suggest that the prognostic signature constructed in the current study may serve as an independent risk factor for HCC. Joint effects analysis of risk scores and clinical features suggested that the prognostic signature may have a strong interaction with clinical features and serve as an independent factor for HCC prognosis. The nomogram substantiated that the risk score contributed most to HCC prognosis prediction. However, because of the lack of validation cohorts, further studies are needed to confirm our results. Functional analysis of these prognostic DELs have rarely been reported in previous studies, therefore, the mechanism underlying the effect of these prognostic DELs on HCC prognosis still needs in-depth exploration.
Functional assessment of the HCC prognostic DELs in PCGs showed that cell cycle biological processes and pathways were significantly enriched. Previous genome-wide screening studies using lncRNA datasets from GEO and TCGA in lung cancer [55, 56] , gastric cancer [44] and breast cancer [57, 58] also identified cell cycle-related lncRNAs. Several studies reported that dysregulation of specific lncRNAs in HCC cell lines caused cell cycle arrest and induced apoptosis, and affected the prognosis of HCC [59, 60] . KEGG enrichment analysis revealed a significant enrichment in the PPAR signaling pathway. Zhang et al. reported that the lncRNA HOTTIP is upregulated and has a high diagnostic value in HCC, and the genes coexpressed with HOTTIP are related to the PPAR signaling pathway [61] . In a genome-wide Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry analysis of intrahepatic cholangiocarcinoma (iCCA), coexpressed mRNAs of DELs in iCCA tissues were significantly enriched in the PPAR signaling pathway, and KEGG enrichment of DEL target genes was demonstrated in papillary thyroid carcinoma [62, 63] . The most enriched functional terms of the KEGG analysis in coexpressed PCGs were metabolism-related pathways, such as glyoxylate and dicarboxylate metabolism, and metabolism of xenobiotics by cytochrome P450. These metabolism-related pathways are associated with liver function and indicating that dysregulated DELs are involved the function of the liver and may play a role in hepatocarcinogenesis. GSEA of low-and high-risk groups demonstrated that cell cycle and PPAR signaling pathways were significantly enriched, and this was confirmed by the PCG enrichment results. We speculate that the prognostic signature identified in the present study may play a vital role in cell cycle and PPAR signaling pathway regulation in HCC. However, these findings need further experimental verification. Although TCGA database was previously used to analyze lncRNA-related signatures for HCC prognosis, the present study was different in that it investigated the optimum combination of these prognostic lncRNAs using the ''step'' function in the R platform [46] . Therefore, the prognostic signature constructed in the present study is more accurate than that identified in a previous study [46] . In addition, comprehensive survival analysis of the present 13-DEL prognostic signature was performed by developing a nomogram, and stratified and joint effects survival analysis was performed to investigate its potential application. The stratified and joint effects analysis of the risk score and clinical features suggested that the 13-DEL prognostic signature was an independent risk factor for HCC, and the associated risk score could serve as a prognostic indicator for HCC patients. The nomogram consisting of the risk score and other clinical information indicated that the contribution of the risk score to HCC prognosis prediction was greater than that of other traditional clinical indicators.
The present study had several limitations. First, the results generated in the present study were derived from a single cohort, and the demographics of the patients from TCGA may not be representative of all patient populations; therefore, the genetic alterations may be biased, and further validation in other HCC cohorts is necessary. Second, the clinical information from TCGA database was incomplete; therefore, we were unable to perform a comprehensive stratification analysis in all strata of HCC, as well as adjust all the features that may affect HCC OS in the Cox proportional hazard regression model.
Despite these limitations, the current study has identified numerous DELs with potential diagnostic and prognostic value for HCC. In addition, we constructed an effective prognostic signature to predict HCC prognosis that may be valuable for clinical application.
Conclusion
Here, we performed a genome-wide screening analysis using an HCC dataset and identified 827 DELs. We then constructed a prognostic signature based on the expression of 13 prognostic DELs. Comprehensive survival analysis of the 13-DEL prognostic signature suggested that the risk score of the prognostic signature serves as an independent factor in HCC and performs better for prognosis prediction than other traditional clinical indicators. The results suggest that the 13-DEL prognostic signature is a potential biomarker for the prognosis of HCC patients, and could be a clinically useful tool that can be easily incorporated into an RNA-Seq clinical sequencing program to individualize HCC therapy. Functional assessment and bioinformatics analysis showed that cell cycle-related processes and pathways and the PPAR signaling pathway were significantly associated with the risk score, indicating that the 13-DEL prognostic signature may be involved in the regulation of the status of HCC cells. However, further studies are necessary to elucidate the mechanism underlying the roles of these DELs in HCC, and additional cohorts are needed to validate our findings. Additional findings of the present study are also worthy of further investigation.
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